Akcea Therapeutics, Inc. Stock News

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) ABIOMED, Inc. (NASDAQ: ABMD) ALX Oncology Holdings Inc (NASDAQ: ALXO) Annexon Inc (NASDAQ: ANNX) Atossa...

Nissay Asset Management Corp Japan ADV grew its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 11.9% in the second quarter, according to its most recent 13F filing with the Securities and Exch

Assenagon Asset Management S.A. bought a new position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exch

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of Austrian Social Security Institutions (Dachverband der

Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to di

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D., Ph.D., has joined the company as senior vice presid

Coastal Investment Advisors Inc. lowered its stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 45.3% during the second quarter, according to its most recent disclosure with the Securities

Stocks Analysis by Zacks Investment Research covering: Ionis Pharmaceuticals Inc, USANA Health Sciences Inc, United Therapeutics Corporation, Theravance Biopharma Inc. Read Zacks Investment Research's

MERIAN GLOBAL INVESTORS UK Ltd lessened its stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 6.4% during the 2nd quarter, according to the company in its most recent filing with the Secur

DNB Asset Management AS raised its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 12.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commiss

The

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joined the company as chief medical officer (CMO